29 May 2024 - NICE has published final evidence-based recommendations on the use of dabrafenib mesylate (Finlee) in combination with trametinib dimethyl sulphoxide (Spexotras) for the treatment of children and adolescents with BRAF V600E mutation positive glioma.

The combination of dabrafenib mesylate and trametinib dimethyl sulphoxide is recommended as an option for the treatment of:

• Low grade glioma with a BRAF V600E mutation in children and adolescents aged 1 year and over who need systemic treatment
• High grade glioma with a BRAF V600E mutation in children and adolescents aged 1 year and over after at least 1 radiation or chemotherapy treatment

Read NICE technology appraisal guidance